| Literature DB >> 32711510 |
Yeda Chen1, Yaoan Wen1, Qingfeng Yu1, Xiaolu Duan1, Wenqi Wu1, Guohua Zeng2.
Abstract
BACKGROUND: Upper urinary tract stones is the most common diseases in urology. Percutaneous nephrolithotomy (PCNL) and ureteroscopic lithotripsy (fURL) are common treatment, but both their efficacy and safety are controversial. Thus we aim to evaluate the efficacy and safety of PCNL and fURL in the treatment of upper urinary tract stones, providing a reference for clinical work.Entities:
Keywords: Efficacy; Percutaneous nephrolithotomy; Safety; Upper urinary tract stones; Ureteroscopic lithotripsy
Mesh:
Year: 2020 PMID: 32711510 PMCID: PMC7382049 DOI: 10.1186/s12894-020-00677-4
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Fig. 1Flow diagram of the literature search and selection
Main characteristic of the included studies
| Reference, year | Nation | primary site | Study design | Surgical technique | Sample size | Age (year) | Sex | Stone burden | Stone side | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median ± range | (Mean ± SD) | Median ± range | (left / right) | |||||||
| Aboutaleb, 2012 [ | Kuwait | Lower calyx | CS | PCNL | 19 | 45.33 ± 14.30 | – | 14/5 | 17.30 ± 3.30 | – | ND |
| fURL | 13 | 47.20 ± 15.20 | – | 7/6 | 14.50 ± 3.20 | – | ND | ||||
| Armagan, 2015 [ | Turkey | Kidney | CS | mPCNL | 68 | 43.60 ± 18.90 | – | 35/33 | 13.70 ± 4.20 | – | ND |
| fURL | 59 | 49.30 ± 15.30 | – | 36/23 | 14.40 ± 3.10 | – | ND | ||||
| Bozkur, 2011 [ | Turkey | Lower calyx | CS | PCNL | 42 | 47.40 ± 15.50 | – | 25/17 | 1.70 ± 0.12 | – | 20/22 |
| fURL | 37 | 41.20 ± 13.60 | – | 21/16 | 1.65 ± 0.69 | – | 19/18 | ||||
| Chung, 2008 [ | America | Kidney | CS | PCNL | 15 | – | 58.00a | 40/60 | – | 1.80 (1.0–2.0) | 60/40 |
| fURL | 12 | – | 58.50a | 58/42 | – | 1.25 (1.0–1.9) | 58/42 | ||||
| Ferroud, 2011 [ | French | Kidney | CS | mPCNL | 101 | 51.70 ± 16.10 | – | 80/21 | 8.90 ± 2.70 | – | ND |
| fURL | 43 | 49.20 ± 14.80 | – | 28/15 | 8.50 ± 3.20 | – | ND | ||||
| Gu, 2013 [ | China | Upper ureter | RCT | mPCNL | 30 | 42.50 ± 10.10 | – | 17/13 | 17.27a | – | 16/14 |
| fURL | 29 | 44.22 ± 13.00 | – | 18/11 | 16.23a | – | 12/17 | ||||
| Hu, 2016 [ | China | ureter | CS | mPCNL | 104 | 65.50 ± 4.90 | – | 56/48 | 15.80 ± 3.40 | – | 53/51 |
| fURL | 80 | 65.10 ± 5.20 | – | 45/35 | 15.80 ± 3.40 | – | 47/33 | ||||
| Kirac, 2013 [ | Turkey | Lower calyx | CS | mPCNL | 37 | 41.02 ± 10.30 | – | 25/12 | 10.50 ± 2.20 | – | 16/22 |
| fURL | 36 | 37.80 ± 8.70 | – | 22/14 | 10.20 ± 2.90 | – | 14/22 | ||||
| Kruck, 2013 [ | Germany | Kidney | CS | mPCNL | 172 | 53.30 ± 14.80 | – | 109/63 | 12.60 ± 9.50 | – | ND |
| fURL | 108 | 50.00 ± 16.70 | – | 69/39 | 6.80 ± 6.90 | – | ND | ||||
| Kumar, 2015 [ | India | Lower calyx | RCT | mPCNL | 41 | 33.70 ± 1.60 | – | 20/21 | 13.30a | – | 22/19 |
| fURL | 43 | 33.40 ± 1.40 | – | 20/23 | 13.10a | – | 22/21 | ||||
| Lee, 2015 [ | Korea | Kidney | RCT | mPCNL | 35 | 59.30 ± 13.30 | – | 28/7 | 39.10a | – | 21/14 |
| fURL | 33 | 55.80 ± 11.20 | – | 28/5 | 28.90a | – | 23/10 | ||||
| Ozgor, 2016 [ | Turkey | Kidney | CS | mPCNL | 56 | 51.40 ± 14.30 | – | 25/31 | 19.50 ± 3.90 | – | 25/31 |
| fURL | 56 | 54.20 ± 10.60 | – | 22/34 | 18.30 ± 3.20 | – | 37/19 | ||||
| Ozgor, 2018 [ | Turkey | Kidney | CS | mPCNL | 58 | 66.90 ± 5.90 | – | 28/30 | 20.30 ± 5.60 | – | ND |
| fURL | 60 | 67.70 ± 6.70 | – | 33/27 | 19.00 ± 4.50 | – | ND | ||||
| Pan, 2013 [ | China | Kidney | CS | mPCNL | 59 | 49.37 ± 14.20 | – | 36/20 | 22.37 ± 2.70 | – | 23/36 |
| fURL | 56 | 49.32 ± 13.70 | – | 37/22 | 22.28 ± 2.60 | – | 30/26 | ||||
| Sabnis, 2012 [ | India | Kidney | CS | mPCNL | 32 | 44.48 ± 12.36 | – | 19/13 | 1.52 ± 0.33 | – | 10/22 |
| fURL | 32 | 49.28 ± 12.19 | – | 25/7 | 1.42 ± 0.34 | – | 16/16 | ||||
| Sabnis, 2013 [ | India | Kidney | RCT | mPCNL | 35 | 38.60 ± 14.60 | – | 22/13 | 11.00a | – | 16/19 |
| fURL | 35 | 43.70 ± 12.10 | – | 24/11 | 10.40a | – | 18/17 | ||||
| Schoenthaler,2015 [ | Germany | Kidney | CS | UMP | 30 | – | 54.30 (19–72) | 17/13 | – | 15.10 (10–20) | ND |
| fURL | 30 | – | 56.30 (18–76) | ND | – | 14.40 (10–20) | ND | ||||
| Wilhelm, 2015 [ | Germany | Kidney | CS | UMP | 25 | – | 51.56 (15–75) | 15/10 | – | 19.28 (10–35) | ND |
| fURL | 25 | – | 51.36 (19–77) | 19/6 | – | 19.20 (10–35) | ND | ||||
| Zhang, 2014 [ | China | Upper ureter | CS | mPCNL | 32 | 42.70 ± 13.60 | – | 24/8 | 15.60 ± 2.50 | – | ND |
| fURL | 44 | 43.30 ± 11.00 | – | 29/15 | 14.90 ± 2.30 | – | ND | ||||
RCT randomized controlled trial, CS cohort study, PCNL percutaneous nephrolithotomy, mPCNL minipercutaneous nephrolithotomy, fURL flexible ureteroscopic lithotripsy, ND not demonstrated
aNo SD or range was demonstrated in primary studies
Fig. 2Risk of bias for randomized controlled trials
Quality assessment of included cohort studies
| Source | Selection | Comparability | Outcome | Scores | |||||
|---|---|---|---|---|---|---|---|---|---|
| Author, year | Representativeness of the exposed cohort | Selection of the non exposed cohort | Ascertainment of exposure | Demonstration that outcome was not present at start of study | select the most important factora | Assessment of outcome | Follow-up long enough | Adequacy of follow up of cohorts | |
| Aboutaleb,2012 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Armagan,2015 [ | – | – | ★ | ★ | ★★ | ★ | – | ★ | 6 |
| Bozkur,2011 [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Chung,2008 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Ferroud,2011 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Hu, 2016 [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Kirac,2013 [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Kruck,2013 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Ozgor,2016 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Ozgor, 2018 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Pan, 2013 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Sabnis,2012 [ | – | – | ★ | ★ | ★★ | ★ | ★ | ★ | 7 |
| Schoenthaler,2015 [ | ★ | ★ | ★ | ★ | ★★ | ★ | – | ★ | 8 |
| Wilhelm,2015 [ | – | – | ★ | ★ | ★★ | ★ | – | ★ | 6 |
| Zhang,2014 [ | – | – | ★ | ★ | ★★ | ★ | – | ★ | 6 |
aA maximum of two stars can be awarded for select the most important factor or additional factor
Fig. 3Forest plots of (a) stone free rate, (b) operative time
Fig. 4Forest plots of (a) decline of Hb, (b) blood transfusion,(c) bleeding or hematuria
Fig. 5Forest plots of (a) fever or infection, (b)perforation,(c) requiring drug analgesia
Results of publication bias testing
| Study project | Included study | Begg testing | Egger testing | 95% CI | ||
|---|---|---|---|---|---|---|
| Stone free rate | 19 | 1.19 | 0.234 | 1.21 | 0.244 | −0.750, 2.750 |
| Operative time | 14 | 0.11 | 0.913 | 1.51 | 0.156 | −2.887, 16.001 |
| Decline of Hb | 7 | 1.5 | 0.133 | −2.13 | 0.101 | −5.691, 0.756 |
| Blood transfusion | 6 | 0.24 | 0.806 | 0.84 | 0.463 | −1.288, 2.208 |
| Bleeding/hematuria | 9 | 0.73 | 0.466 | 1.36 | 0.216 | −0.934, 2.204 |
| Fever/infection | 12 | 0.89 | 0.373 | −1.22 | 0.251 | −2.639, 0.774 |
| Perforation | 6 | 0.38 | 0.707 | −0.6 | 0.578 | −8.271, 5.314 |
| Requiring drug analgesia | 5 | 0.24 | 0.806 | 0.56 | 0.615 | −5.318, 7.599 |